title: The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells.
abstract: Retinoic acids and their derivatives potentiate anti-cancer effects in breast cancer cells. The aberrant expression of telomerase is critical to the continued proliferation of most cancer cells. Thus, telomerase is an attractive target for chemoprevention and treatment of breast cancer. 9cUAB30 is a novel synthetic retinoid X receptor-selective retinoic acid (RA) that effectively reduces the tumorigenic phenotype in mouse breast carcinoma with lower toxic effects than natural retinoid treatments. We have assessed 9cUAB30 retinoic acid treatment of human breast cancer cells to determine the potential of this drug as an effective telomerase inhibitor and its application to cancer therapy. 9cUAB30 was found to decrease DNA methyltransferase and telomerase expression in MDA-MB-361, T-47D, and MCF-7 human breast cancer cells and to inhibit the proliferation of these cells. This low-toxicity retinoid also reduced colony formation in soft agar assays in each of these cell types. Combination treatments of 9cUAB30 and all-trans RA proved to be synergistically more effective than either RA alone, further suggesting a possible general epigenetic mechanism that contributes to the anti-telomerase activity of the retinoids. Therefore, the novel retinoid, 9cUAB30, is effective in inhibiting the growth of human breast cancer cells, its anti-cancer effects appear to be related to telomerase inhibition and the mechanism for this process could be mediated through epigenetic modifications.
authors.affiliation: Department of Biology, University of Alabama at Birmingham, 1300 University Boulevard, Birmingham, AL 35294, USA.
authors.forename: Nathan J
authors.initials: NJ
authors.lastname: Hansen
authors.forename: Rebecca C
authors.initials: RC
authors.lastname: Wylie
authors.forename: Sharla M O
authors.initials: SM
authors.lastname: Phipps
authors.forename: William K
authors.initials: WK
authors.lastname: Love
authors.forename: Lucy G
authors.initials: LG
authors.lastname: Andrews
authors.forename: Trygve O
authors.initials: TO
authors.lastname: Tollefsbol
mesh_terms: D017209:Apoptosis; D001943:Breast Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005231:Fatty Acids, Unsaturated / Q000096:biosynthesis*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009281:Naphthalenes; D012176:Retinoids / Q000378:metabolism; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D013997:Time Factors; D014212:Tretinoin / Q000378:metabolism
chemical_list: D005231:Fatty Acids, Unsaturated; D009281:Naphthalenes; D012176:Retinoids; D014212:Tretinoin; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; D019098:Telomerase; C112106:UAB 30